The plan seeks to turn the Kingdom into a biotech innovation and economic hub, offering new jobs and contributing 3% to the non-oil GDP (SR130 billion) by 2040. This initiative is pivotal for the country's goal of becoming a key biotech player worldwide.

Aligned with Vision 2030 goals, the strategy aims to bolster national health resilience and capitalize on the rapidly growing biotech industry.

The strategy document sets forth Saudi Arabia's biotech potential and the steps to achieve it, focusing on health improvement, economic stimulation, job creation, investment attraction, and sustainable development.

The Kingdom aspires to be MENA's top biotech destination by 2030 and a global hub by 2040, leveraging its capital, market size, government support, and unique gene reservoir to excel in vaccines, bio-manufacturing, genomics, and plant optimization.

The strategy includes creating vaccine technologies and cultivating biomanufacturing locally, enhancing Saudi self-reliance, and securing vaccine access. These efforts are key to establishing Saudi Arabia as a biotech leader in the MENA region and globally.

Advanced biopharma capabilities and a comprehensive bio-manufacturing platform are also critical, improving treatment availability and strengthening the local industry's international profile.

Aiming to lead MENA in genomics, the Kingdom will drive innovation and health outcomes. Plant optimization efforts will boost food security and sustainable agriculture, lessening food import dependence and increasing self-sufficiency.

A suite of initiatives will remove hurdles in talent, regulation, funding, and infrastructure to mature Saudi Arabia's biotech ecosystem. This strategy promises to accelerate the sector's growth, coordinate ecosystem efforts, create high-quality jobs, and open up new investment and career opportunities in biotech.